Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring between April 9, 2026, and April 21, 2026. Celularity Inc. (CELU), an emerging growth company, reported material agreements regarding the divestiture of its biomaterials business to NexGel, Inc., a default notice on a convertible note, and significant leadership changes.
Key Financial Metrics and Obligations
- Asset Sale Consideration: Total consideration for the NexGel transaction is $13.3 million, comprising an $8.3 million upfront cash payment and a $5.0 million convertible promissory note (18-month term).
- Milestone Payments: A $2.5 million milestone is payable upon the earlier of achieving $25.0 million in net sales or 15 months post-commencement (contingent on $15.0 million in net sales).
- Debt Obligation: A $1,970,502.58 Convertible Promissory Note (Helena Note) was created via exchange of Series A Preferred Stock. It bears 18.0% annual interest and matures October 16, 2026.
- Default Penalties: If the default on the Helena Note is not cured, the "Mandatory Default Amount" equals 115% of principal and accrued interest, with interest accruing at 15% compounded annually.
Material Changes and Events
- Transaction Amendment: The agreement with NexGel was amended to terminate a product purchase credit and extend the outside date to April 30, 2026. NexGel assumed all sales representative obligations.
- Event of Default: Helena Global Investment Opportunities 1 Ltd. issued a Default Notice on April 17, 2026, citing the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2025.
- Leadership Departures: John R. Haines (SVP, Global Manager, and CAO) was terminated without cause (final day May 8, 2026). Stephen A. Brigido (President, Degenerative Diseases) resigned effective April 15, 2026.
Outlook, Risks, and Management Commentary
Management stated that leadership changes reflect a strategic realignment to focus resources on the core cell therapy platform. The Company intends to cure the asserted default on the Helena Note within the five-business-day cure period. The filing highlights the risk of accelerated debt repayment and increased interest rates if the filing delinquency is not resolved promptly.
Investor Verification Checklist
- Verify the status of the Form 10-K filing for the fiscal year ended December 31, 2025, to confirm if the default on the Helena Note has been cured.
- Confirm the receipt of the $8.3 million upfront cash payment from NexGel.
- Review the terms of the $5.0 million convertible note issued to NexGel for conversion triggers and covenants.
- Monitor for further announcements regarding the Company's organizational structure following the departure of senior executives.